ICCS 2026 tests CellView imaging as a single-cell check for rare plasma-cell MRD events
Summary
Waters Biosciences lists an ICCS 2026 poster using CellView imaging to verify the single-cell origin of rare abnormal plasma-cell events in measurable residual disease research. CFCM publishes the signal as WATCH because public conference material does not yet provide diagnostic-performance data.
Source Date
Source checked
October 6, 2026
Event Type
ICCS scientific poster / image-enabled rare-event verification signal
Event Date
Geography
ICCS 2026, Miami, USA / global RUO research market
Commercial Regulatory Status
Included in the ICCS 2026 program on the FACSDiscover A8/CellView research platform. The listing does not verify a completed presentation day. The A8/CellView platform is Research Use Only; the poster does not establish diagnostic authorization.
Related CFCM Topics
ICCS 2026; Measurable Residual Disease; Plasma Cell Disorders; Imaging Flow Cytometry; Rare Event Analysis; Troubleshooting; Evidence
Category
Technology
Primary source
Read the source →Facts supported by cited sources
Waters Biosciences lists ICCS poster 133, Visualizing Measurable Residual Disease: CellView Imaging confirms the Single-Cell Origin of Rare Abnormal Plasma Cells. Current product documentation describes FACSDiscover A8 as a spectral analyzer with real-time CellView imaging and image-derived morphological parameters, allowing individual events to be visualized alongside conventional flow measurements.
CFCM explainer
Rare event enters an MRD gate → CellView image check → single cell vs doublet/aggregate → retain or challenge the event.
Source/credit: CFCM conceptual schematic based on the Waters ICCS 2026 poster listing and FACSDiscover A8/CellView product documentation. Alt text: rare-event MRD gate followed by image-based single-cell verification.
Claims Requiring Caution
The public ICCS page provides the poster title and authors but not the underlying sample size, gating criteria, false-positive rate, analytical sensitivity, specificity, limit of detection or external-site validation. The title supports a use case, not proof that imaging improves clinical MRD accuracy.
Why It Matters
Rare-event analysis is vulnerable to doublets, aggregates and visually implausible events that can survive numerical gates. Event-level imaging could add an orthogonal check by showing whether the gated event is actually a single cell. The next evidence threshold is whether that reduces false positives without losing true rare events.
An announcement is not proof of availability or authorisation. Interpret status within the stated jurisdiction and evidence boundary.
Editor and independence disclosure →